Dexcom (DXCM) Long-Term Deferred Tax (2020 - 2026)

Dexcom (DXCM) has 7 years of Long-Term Deferred Tax data on file, last reported at $296.1 million in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $296.1 million, down 39.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $296.1 million (down 39.24% YoY), and the FY2025 annual result was $295.6 million, down 38.57% from the prior year.
• Long-Term Deferred Tax steadied at $296.1 million in Q1 2026 per DXCM's latest filing, from $295.6 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $501.3 million in Q3 2023 and troughed at $290.8 million in Q1 2022.
• A 5-year average of $401.5 million and a median of $417.0 million in 2023 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax jumped 58.25% in 2022, then slumped 39.24% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $341.2 million in 2022, then grew by 22.92% to $419.4 million in 2023, then climbed by 14.74% to $481.2 million in 2024, then sank by 38.57% to $295.6 million in 2025, then grew by 0.17% to $296.1 million in 2026.
• Business Quant data shows DXCM's Long-Term Deferred Tax at $296.1 million in Q1 2026, $295.6 million in Q4 2025, and $375.6 million in Q3 2025.